Page 3 - Mark Corbae News Today

Investegate announcements from Cybrexa Therapeutics, Cybrexa Therapeutics Announces Data Demonstrating Early Signals of Efficacy and Powerful Potential of Antigen-Independent Tumor Targeting

The Colorado Attorney General is investigating a Denver-based company that is the nation’s largest provider in a federal community-based home health program for frail, elderly patients, initiating the probe after

Virginia Centers Join Centers in Three Other States in Achieving Certification by the National Committee for Quality Assurance...

Sirnaomics Announces Acceptance of Investigational New Drug Application by China NMPA for Global Multicenter Phase 2b Trial of STP705 Treatment for Skin Squamous Cell Carcinoma News provided by Share this article Share this article GAITHERSBURG, Md. and SUZHOU BIOBAY, China, June 16, 2021 /PRNewswire/ -- Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer, fibrotic diseases, and other unmet clinical indications, today annou...

BETHESDA, Md.--(BUSINESS WIRE)--Longhorn Vaccines & Diagnostics, an innovative molecular tool, assay and vaccine development company focused on serving unmet critical needs in both developed and developing nations, announced today that it has been selected to deliver a presentation on the past success and future opp...

(0) - Study to determine safety and tolerability of CBX-12 and establish recommended Phase 2 dose - NEW HAVEN, Conn., May 10, 2021 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex Peptide Drug Conjugate (PDC) tumor targeting platform, today announced the first patient has been dosed in a Phase 1/2 clinical trial evaluating CBX-12 (alphalex-exatecan), the companys lead therapeutic candidate. The open-l...

Published: Apr 29, 2021   GAITHERSBURG, Md. and SUZHOU BIOBAY, China, April 29, 2021 /PRNewswire/ -- Sirnaomics (Suzhou) Co. Ltd., a subsidiary of Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer, fibrotic diseases and viral infections, announced today that the company has entered into a partnership agreement with Walvax Biotechnology (Walvax) for the co-development of its anti-influenza siRNA therapeutic product can...

Share this article Share this article GAITHERSBURG, Md. and SUZHOU BIOBAY, China, April 29, 2021 /PRNewswire/ -- Sirnaomics Biopharmaceuticals (Suzhou) Co. Ltd., a subsidiary of Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer, fibrotic diseases and viral infections, announced today that the company has entered into a partnership agreement with Walvax Biotechnology (Walvax) for the co-development of its anti-influenza siR...

Sirnaomics Initiates Phase 2b Study Using STP705 for Treatment of Squamous Cell Skin Cancer Company Expects to Report Initial Clinical Data in Second Half of 2021 News provided by Share this article Share this article GAITHERSBURG, Md. and SUZHOU BIOBAY, China, April 25, 2021 /PRNewswire/ -- Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced the initiation of the Phase 2b study of the...

Sirnaomics Initiates Phase 2 Study Using STP705 for Keloid Scar Prevention Company Expects to Report Interim Clinical Data in the Second Half of 2021 News provided by Share this article Share this article GAITHERSBURG, Md. and SUZHOU BIOBAY, China, April 18, 2021 /PRNewswire/ -- Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced the initiation of a Phase 2 study of the companys lead d...